| Date of authorisation by the Extraordinary General Meeting | 30.06.2020 | 21.04.2022 | 21.04.2023 | 23.04.2024 |
|---|---|---|---|---|
| Date of grant by the Board of Directors | Date of grant by the Board of Directors 30.06.2020 07.10.2021 |
Date of grant by the Board of Directors 21.04.2022 13.10.2022 |
Date of grant by the Board of Directors 21.04.2023 12.10.2023 |
Date of grant by the Board of Directors 23.04.2024 10.10.2024 |
| Total number of shares conditionally granted | Total number of shares conditionally granted 30.06.2020 588,750 |
Total number of shares conditionally granted 21.04.2022 700,000 |
Total number of shares conditionally granted 21.04.2023 650,580 |
Total number of shares conditionally granted 23.04.2024 700,000 |
| Of which the 10 employees other than corporate officers granted the largest number of shares(1) | Of which the 10 employees other than corporate officers granted the largest number of shares(1) 30.06.2020 72,400 |
Of which the 10 employees other than corporate officers granted the largest number of shares(1) 21.04.2022 78,400 |
Of which the 10 employees other than corporate officers granted the largest number of shares(1) 21.04.2023 70,650 |
Of which the 10 employees other than corporate officers granted the largest number of shares(1) 23.04.2024 73,175 |
| Number of beneficiaries | Number of beneficiaries 30.06.2020 2,408 |
Number of beneficiaries 21.04.2022 2,647 |
Number of beneficiaries 21.04.2023 2,763 |
Number of beneficiaries 23.04.2024 2,742 |
| Performance conditions | Performance conditions 30.06.2020
|
Performance conditions 21.04.2022
|
||
| Date of vesting | Date of vesting 30.06.2020 08.10.2025 |
Date of vesting 21.04.2022 14.10.2026 |
Date of vesting 21.04.2023 13.10.2027 |
Date of vesting 23.04.2024 11.10.2028 |
| End of lock-in period | End of lock-in period 30.06.2020 N/A |
End of lock-in period 21.04.2022 N/A |
End of lock-in period 21.04.2023 N/A |
End of lock-in period 23.04.2024 N/A |
At its meeting on 6 February 2025, the Board of Directors found that 100% of the performance conditions were achieved during the three years taken into consideration by the ACAs plan of 7 October 2021, namely 2022, 2023 and 2024. Accordingly, the beneficiaries who fulfil the conditions of the plan on 7 October 2025 and, in particular, that relating to the condition of presence in the Company, will receive 100% of the shares that were granted to them.
For the record, 17,000 shares were granted to Nicolas Hieronimus, Chief Executive Officer, under the 7 October 2021 Plan. After application of the plan terms, 17,000 shares will ultimately vest to Nicolas Hieronimus.
| ACAs plan of 7 October 2021 | 2022 | 2023 | 2024 | Arithmetic average of performances for financial years 2022, 2023 and 2024 |
|---|---|---|---|---|
|
50% growth in like-for-like sales compared to a panel of competitors* |
50% growth in like-for-like sales compared to a panel of competitors* 2022 +7.3 points(+10.9%/+3.6%) |
50% growth in like-for-like sales compared to a panel of competitors* 2023 +5.8 points(+11.0%/+5.2%) |
50% growth in like-for-like sales compared to a panel of competitors* 2024 +2 points(+5.1%/+3.1%) |
50% growth in like-for-like sales compared to a panel of competitors* Arithmetic average of performances for financial years 2022, 2023 and 2024 +5.03 points |
| 50% change in the Group’s operating profit | 50% change in the Group’s operating profit 2022 +21.00%(6,160.3/7,456.9) |
50% change in the Group’s operating profit 2023 +9.20%(7,456.9/8,143.3) |
50% change in the Group’s operating profit 2024 +6.68%(8,143.3/8,687.5) |
50% change in the Group’s operating profit Arithmetic average of performances for financial years 2022, 2023 and 2024 +12.29% |
